{"id":798798,"date":"2025-01-08T07:07:15","date_gmt":"2025-01-08T12:07:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/"},"modified":"2025-01-08T07:07:15","modified_gmt":"2025-01-08T12:07:15","slug":"biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/","title":{"rendered":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey<\/b><\/p>\n<p>DUBLIN&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=54175214&amp;newsitemid=20250108086626&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=2ae444bf6e68de7a603d9ae280038e65\">ICON plc<\/a>, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer&#8217;s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies.<\/p>\n<p>\nICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: \u2018Early, precise and efficient: The methods and technologies advancing Alzheimer\u2019s and Parkinson\u2019s R&amp;D\u2019.<\/p>\n<p>\nBiomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation. The use of biomarkers can sometimes make a trial longer, more expensive, and slower to enrol patients. However, implementation of biomarker tests could be increasingly implemented to address some of the more resource-intensive eligibility criteria, such as imaging or CSF status.<\/p>\n<p>\nInnovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only 28% of respondents reported implementing an adaptive trial design of any type, while even fewer reported using historic controls (22%) or master protocol designs (19%), all of which can accelerate patient recruitment.<\/p>\n<p>\nPeter Schueler, MD, Senior Vice President, Drug Development Solutions, Neurosciences at ICON commented: <i>\u201cNeurodegenerative clinical research is exceptionally complex and challenging. The main two roadblocks survey respondents identified for innovative tools were costs and difficulty validating the impact. At ICON, we believe that the industry can make more use of lessons learned from recent successes in Alzheimer\u2019s and continue to turn the tide in related indications such as Parkinson\u2019s.\u201d<\/i><\/p>\n<p>\nEncouragingly, the survey revealed sponsors are not deterred from investing in R&amp;D, especially in a diversified way. A large majority of respondents (87%) reported that they plan to invest in multiple therapeutic areas or a combination approach. They are also using AI to accelerate R&amp;D, predominantly for the initial steps of the development process. For example, half of respondents who reported using AI or machine learning employ it for hypothesis generation (48%) and lead discovery (50%).<\/p>\n<p>\nInterestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only 29% of respondents indicated that it was an area that could support and accelerate R&amp;D.<\/p>\n<p>\nPeter Schueler observed: <i>\u201cThe recent successes in developing treatments for Alzheimer&#8217;s disease can be attributed, in part, to improvements in trial design and execution. Replicating and improving upon this initial clinical success is essential to alleviate the growing burden of neurodegenerative diseases. Further engagement is needed across the clinical trial ecosystem \u2013 with established platforms, advocacy groups, biotech and pharma \u2013 to examine how best to work together in a way that balances the practicalities and risks associated with this complex therapeutic research field.\u201d<\/i><\/p>\n<p>\nFor further information on this whitepaper, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2FCNS-trials&amp;esheet=54175214&amp;newsitemid=20250108086626&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.iconplc.com%2FCNS-trials&amp;index=2&amp;md5=04cdab5b999282980980ed5efa7541bc\">http:\/\/www.iconplc.com\/CNS-trials<\/a><\/p>\n<p><b>About ICON plc<\/b><\/p>\n<p>\nICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 42,250 employees in 106 locations in 55 countries as at September 30, 2024. For further information about ICON, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com&amp;esheet=54175214&amp;newsitemid=20250108086626&amp;lan=en-US&amp;anchor=www.iconplc.com&amp;index=3&amp;md5=e1bd3e772e0ca7ef1f4e52a33379adcb\">www.iconplc.com<\/a>.<\/p>\n<p>\nICON\/ICLR-G<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250108086626\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250108086626\/en\/<\/a><\/span><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Claire Quinn, Corporate Communications, ICON<br \/>\n<br \/>+353 87 4066091<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:claire.quinn@iconplc.com\">claire.quinn@iconplc.com<br \/>\n<\/a><\/p>\n<p>Lisa Henry, Weber Shandwick (PR adviser)<br \/>\n<br \/>+44 7785 458203<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lhenry@webershandwick.com\">lhenry@webershandwick.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe Ireland United Kingdom<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Neurology Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250108086626\/en\/2347147\/3\/ICON_logo_high_res.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey DUBLIN&#8211;(BUSINESS WIRE)&#8211;ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer&#8217;s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: \u2018Early, precise and efficient: The methods and technologies advancing Alzheimer\u2019s and Parkinson\u2019s R&amp;D\u2019. Biomarkers are one of the most promising &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798798","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey DUBLIN&#8211;(BUSINESS WIRE)&#8211;ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer&#8217;s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: \u2018Early, precise and efficient: The methods and technologies advancing Alzheimer\u2019s and Parkinson\u2019s R&amp;D\u2019. Biomarkers are one of the most promising &hellip; Continue reading &quot;Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T12:07:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey\",\"datePublished\":\"2025-01-08T12:07:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/\",\"name\":\"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-01-08T12:07:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/","og_locale":"en_US","og_type":"article","og_title":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk","og_description":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey DUBLIN&#8211;(BUSINESS WIRE)&#8211;ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer&#8217;s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: \u2018Early, precise and efficient: The methods and technologies advancing Alzheimer\u2019s and Parkinson\u2019s R&amp;D\u2019. Biomarkers are one of the most promising &hellip; Continue reading \"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T12:07:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey","datePublished":"2025-01-08T12:07:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/","name":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-01-08T12:07:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250108086626r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biomarker-and-trial-optimisation-needed-to-drive-rd-progress-in-alzheimers-and-related-disorders-icon-survey\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biomarker and Trial Optimisation Needed to Drive R&amp;D Progress in Alzheimer\u2019s and Related Disorders \u2013 ICON Survey"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798798"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798798\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}